#NRIX hashtag - Bluesky

Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Expand bexobrutideg into autoimmune and inflammatory indications,

2 months ago

#NRIX Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

www.stocktitan.net/news/NRIX/nurix-therapeu...

0 0 0 0

TickerTalksAI

@tickertalksai.bsky.social

2 months ago

📈 $NRIX +95% upside | Morgan Stanley upgrades to Overweight, raises target to $36 | Bexdeg BTK degrader success rate 60% | CLL cancer play | Watch 2027-2028 pivotal trial data

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

3 months ago

Leading Indicators, Tuesday December 9, 2025 – Crystal Equity Research

Small-cap stocks overbought with declining relative strength, Tue Dec 9th - #SND #NRIX #MAZE #GLUE #COLL #ATNI #APAD #GSL - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

5 months ago

#NRIX Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

www.stocktitan.net/news/NRIX/nurix-therapeu...

1 0 0 0

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the

5 months ago

#NRIX Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock

www.stocktitan.net/news/NRIX/nurix-therapeu...

1 0 0 0

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia Nurix (Nasdaq: NRIX) initiated the DAYBreak pivotal single-arm Phase 2 study of bexobrutideg (NX-5948) in relapsed or refractory chronic lymphocytic leukemia (r/r CLL) on October 22, 2025. The program will evaluate a 600 mg once-daily oral dose cleared by global regulators for pivotal monotherapy trials and seeks data to support a potential Accelerated Approval.Nurix plans a randomized confirmatory Phase 3 to start in the first half of 2026 comparing bexobrutideg to pirtobrutinib, bendamustine + rituximab, or idelalisib + rituximab. An investor webcast occurred October 22, 2025 at 8:00 a.m. EDT reviewing preclinical data and program updates.

5 months ago

#NRIX Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

www.stocktitan.net/news/NRIX/nurix-initiate...

1 0 0 0

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Nurix Therapeutics (Nasdaq: NRIX) reported Q3 2025 results and program updates on Oct 9, 2025. The company plans to initiate pivotal studies for bexobrutideg in relapsed/refractory CLL in H2/Q4 2025, including a single‑arm path for potential accelerated approval and a randomized Phase 3 confirmatory trial. Encore Phase 1 data showed ORR 80.9% in CLL and ORR 84.2% in WM. Preclinical data for IRAK4 degrader GS-6791 were presented. Cash and marketable securities were $428.8M as of Aug 31, 2025.

5 months ago

#NRIX Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/NRIX/nurix-therapeu...

1 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

Leading Indicators, Thursday July 31, 2025 – Crystal Equity Research

Small-cap stocks in new downtrend with AROON Oscillator, Thu Jul 31st - #OSBC #NRIX #MODV #LOCO #KRT #INMD #HYPD #GYRE #FLGC #ENSC #TWST #DENN #CXDO #BWAY #ATEC #WSR #TYG #SQNS #OEC #MYE #LAW #SPT #KYX #IPI #HVT #GPRK #FINV - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

8 months ago

Nurix Advances Targeted Protein Degradation Pipeline with Clinical and Partnership Milestones Nurix Therapeutics (Nasdaq: NRIX) is gaining traction as its stock rose 20% in premarket trading after the company reported second quarter 2025 results yesterda

#NurixTherapeutics #NRIX surged 20% as Nurix Therapeutics ramps up progress in targeted protein degradation. With new CLL data, pivotal trials ahead, and expanded deals with #Gilead #GILD and #Sanofi #SNY, this biotech is gaining serious traction.
Full Story: prismmarketview.com/nurix-advanc...

1 0 0 0

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Nurix Therapeutics (Nasdaq: NRIX) reported significant progress in Q2 2025, highlighted by positive clinical developments and strategic collaborations. The company presented updated data for bexobrutideg (NX-5948), showing an impressive 80.9% objective response rate in r/r CLL patients. Nurix secured a $15M license fee from Sanofi's STAT6 collaboration extension and received FDA clearance for IRAK4 degrader GS-6791/NX-0479.Financial highlights include Q2 2025 revenue of $44.1M, up from $12.1M year-over-year, and a strong cash position of $485.8M. R&D expenses increased to $78.1M from $48.9M, while net loss improved to $43.5M ($0.52 per share) compared to $44.5M ($0.71 per share) in Q2 2024.

8 months ago

#NRIX Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/NRIX/nurix-therapeu...

0 0 0 0

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia Nurix Therapeutics (Nasdaq: NRIX) announced that its drug bexobrutideg (NX-5948) has received Orphan Drug Designation from the European Medicines Agency for treating lymphoplasmacytic lymphoma, also known as Waldenström macroglobulinemia (WM).The designation provides significant benefits including 10 years of market exclusivity in the EU upon approval, protocol assistance, and reduced regulatory fees. Bexobrutideg, an oral BTK degrader, is currently in Phase 1a/b clinical trials for relapsed or refractory B-cell malignancies.The drug has already received multiple regulatory designations, including FDA Fast Track for WM and CLL/SLL treatment, and EMA PRIME designation for CLL/SLL treatment, demonstrating strong regulatory momentum.

8 months ago

#NRIX European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

www.stocktitan.net/news/NRIX/european-medic...

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

9 months ago

Nurix Reports Durable, Deepening Responses With Bexobrutideg in Hard-to-Treat Blood Cancers Nurix Therapeutics (NASDAQ: NRIX) presented new clinical data at EHA 2025 showing sustained responses with its investigational BTK degrader bexobrutideg (NX-594

#NRIX Delivers Promising Results in Blood Cancer Fight
Nurix has reported durable and deepening responses with its investigational therapy Bexobrutinib (NX-2127) in patients with hard-to-treat blood cancers.
#NurixTherapeutics
prismmarketview.com/nurix-report...

0 0 0 0

Sanofi Bets Big on Nurix: $465M Deal for Revolutionary Inflammation Drug That Could Transform Asthma Treatment Sanofi expands partnership with $15M upfront payment for STAT6 degrader program targeting atopic dermatitis and asthma. Total deal value exceeds $592M. See details.

10 months ago

#NRIX Sanofi Exercises License Extension Option to Nurix’s STAT6 Program

www.stocktitan.net/news/NRIX/sanofi-exercis...

0 0 0 0

FDA Green Lights Groundbreaking IRAK4 Degrader: $420M Milestone Potential in Inflammatory Disease Fight New IRAK4 degrader shows promising arthritis efficacy. Gilead partnership unlocks $5M milestone, with $420M more possible. See trial timeline and profit-sharing details.

11 months ago

#NRIX Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

www.stocktitan.net/news/NRIX/nurix-announce...

0 0 0 0

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update Nurix Therapeutics (NRIX) reported Q1 2025 financial results and corporate updates. The company's lead BTK degrader NX-5948 received the nonproprietary name 'bexobrutideg' and FDA Orphan Drug Designation for Waldenström macroglobulinemia. Revenue increased to $18.5M from $16.6M year-over-year, including $7M in Sanofi collaboration milestones.The company achieved significant milestones, including a $15M license extension fee from Sanofi and strengthened its leadership with Roy D. Baynes joining the board and John Northcott as chief commercial officer. R&D expenses rose to $69.7M from $50.0M, while G&A expenses slightly decreased to $11.7M.The company reported a net loss of $56.4M ($0.67 per share) compared to $41.5M ($0.76 per share) in the previous year. Nurix maintains a strong financial position with $549.7M in cash and marketable securities, excluding recent milestone payments.

11 months ago

#NRIX Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/NRIX/nurix-therapeu...

0 0 0 0

Major Pharma Deal: Nurix's AI Platform Lands $480M Potential Sanofi Partnership Nurix expands Sanofi collaboration with new AI-driven drug discovery program, securing $15M upfront and $465M in potential milestones. Full deal analysis inside.

1 year ago

#NRIX Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

www.stocktitan.net/news/NRIX/nurix-licenses...

0 0 0 0

Revolutionary AI Platform Drives 4 Cancer Drug Innovations: Nurix AACR 2025 Spotlight New DEL-AI platform reveals breakthrough cancer treatments: brain-penetrating degraders and Aurora A inhibitors. Four major presentations showcase pipeline advances.

1 year ago

#NRIX Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

www.stocktitan.net/news/NRIX/nurix-therapeu...

0 0 0 0

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia Nurix Therapeutics (NRIX) announced that its drug bexobrutideg (NX-5948) has received Orphan Drug Designation (ODD) from the FDA for treating Waldenström macroglobulinemia (WM). Bexobrutideg is an oral, brain-penetrant BTK degrader currently in Phase 1a/b clinical trials for relapsed/refractory B-cell malignancies.The ODD grants several benefits including tax credits for clinical testing, FDA fee waivers, and seven years of market exclusivity upon approval. The drug represents a new class of targeted protein degraders, marked by the novel 'deg' suffix, distinguishing it from traditional inhibitors that use the 'ib' suffix.The designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström Macroglobulinemia. The drug's mechanism involves catalytic degradation of target proteins through the proteasome, potentially eliminating mutant oncoproteins resistant to inhibitor therapy.

1 year ago

#NRIX Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

www.stocktitan.net/news/NRIX/nurix-announce...

1 0 0 0

Game-Changing Cancer Drug Shows 75.5% Success Rate: Nurix's Breakthrough Treatment Gains Fast-Track Status Nurix reports promising 75.5% response rate for NX-5948 in CLL/SLL patients, earning both EMA PRIME and FDA Fast Track status. Strong $609.6M cash position supports 2025 pivotal trials.

1 year ago

#NRIX Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/NRIX/nurix-therapeu...

0 0 0 0

Nurix's NX-5948 Cancer Drug Achieves 75% Response Rate, Secures Fast Track Status Nurix Therapeutics reports strong clinical results for NX-5948 in leukemia treatment, receiving FDA Fast Track and EMA PRIME designations. $609.6M cash runway extends to 2027.

1 year ago

#NRIX Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases

www.stocktitan.net/news/NRIX/nurix-therapeu...

0 0 0 0

Nurix's BTK Degrader NX-5948 Earns FDA Fast Track Status for Rare Blood Cancer Treatment Nurix Therapeutics secures FDA Fast Track designation for NX-5948 in Waldenstrom's macroglobulinemia, building on recent regulatory wins and promising Phase 1 data.

1 year ago

#NRIX Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia

www.stocktitan.net/news/NRIX/nurix-therapeu...

0 0 0 0

1 year ago

NEWS: ( NASDAQ: #NRIX ) Outperform Recommendation Issued On NRIX By BMO Capital

#StockMarket #News

0 0 0 0

1 year ago

BREAKING NEWS: ( NASDAQ: #NRIX ) NRIX Price Target Alert: $35.00. Issued by BMO Capital

#StockMarket #News

0 0 0 0

1 year ago

#NRIX Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

www.stocktitan.net/news/NRIX/nurix-therapeu...

0 0 0 0

1 year ago

#NRIX Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

www.stocktitan.net/news/NRIX/nurix-therapeu...

0 0 0 0

1 year ago

NEWS: ( NASDAQ: #NRIX ) Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

#StockMarket #News

0 0 0 0

1 year ago

#NRIX Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

www.stocktitan.net/news/NRIX/nurix-therapeu...

0 0 0 0